Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients

NCT00249171 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT00249171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00249171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2001
Completion date
February 28, 2003
Enrollment
226 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

emergency treatment, psychotic disorders, schizophrenia